Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L BhattMichael SzarekBertram PittChristopher P CannonLawrence A LeiterDarren K McGuireJulia B LewisMatthew C RiddleSilvio E InzucchiMikhail N KosiborodDavid Z I CherneyJamie P DwyerBenjamin M SciricaClifford J BaileyRafael DíazKausik K RayJacob A UdellRenato D LopesPablo LapuertaPhillippe Gabriel Stegnull nullPublished in: The New England journal of medicine (2020)
In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).